Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-α inhibitor

被引：3

作者：

Lee, Eun Jung ^{[1
]}

Song, Ran ^{[1
]}

Park, Ji-Na ^{[1
]}

Lee, Yeon-Ah ^{[1
]}

Son, Jun Seong ^{[2
]}

Hong, Seung-Jae ^{[1
]}

Yang, Hyung-In ^{[1
]}

Lee, Sang-Hoon ^{[1
]}

机构：

[1] Kyung Hee Univ, Dept Rheumatol, E W Neo Med Ctr, Ctr Arthrit & Rheumatism,Sch Med, Seoul 134727, South Korea

[2] Kyung Hee Univ, Dept Infect Dis, Seoul 134727, South Korea

来源：

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2010年 / 13卷 / 03期

关键词：

ankylosing spondylitis; chronic necrotizing pulmonary aspergillosis; etanercept; tumor necrosis factor-alpha; RHEUMATOID-ARTHRITIS; INFECTIONS; ETANERCEPT; THERAPY; INFLIXIMAB; BLOCKADE;

D O I：

10.1111/j.1756-185X.2010.01528.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tumor necrosis factor (TNF)-alpha is a pro-inflammatory cytokine that plays an important role in the pathogenesis of a variety of autoimmune diseases. TNF-alpha inhibitors have been shown to offer clinical benefits in the treatment of autoimmune and inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis (AS), and Crohn's disease. Occasionally, these agents have been associated with infectious complications because of their immunosuppressive activity. Globally, several cases of infections associated with TNF-alpha inhibitors have been reported. However, Aspergillus infection associated with etanercept is very rare. We report a case of chronic necrotizing pulmonary aspergillosis in a 51-year-old man with AS that developed after treatment with etanercept.

引用

页码：e16 / e19

页数：4

共 13 条

[1] CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS - A DISCRETE CLINICAL ENTITY [J].

BINDER, RE ;

FALING, LJ ;

PUGATCH, RD ;

MAHASAEN, C ;

SNIDER, GL .

MEDICINE, 1982, 61 (02) :109-123

[2] Infections and biological therapy in rheumatoid arthritis [J].

Cunnane, G ;

Doran, M ;

Bresnihan, B .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2003, 17 (02) :345-363

[3] Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? [J].

Ehlers, S .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S199-S203

[4] Infections and anti-tumor necrosis factor α therapy [J].

Ellerin, T ;

Rubin, RH ;

Weinblatt, ME .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3013-3022

[5]

*FDA, 2001, SAF UPD TNF ANT INFL

[6] Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus [J].

Mambula, SS ;

Sau, K ;

Henneke, P ;

Golenbock, DT ;

Levitz, SM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39320-39326

[7] Immune function in patients with rheumatoid arthritis treated with etanercept [J].

Moreland, LW ;

Bucy, RP ;

Weinblatt, ME ;

Mohler, KM ;

Spencer-Green, GT ;

Chatham, WW .

CLINICAL IMMUNOLOGY, 2002, 103 (01) :13-21

[8] Infections associated with tumor necrosis factor-α antagonists [J].

Rychly, DJ ;

DiPiro, JT .

PHARMACOTHERAPY, 2005, 25 (09) :1181-1192

[9] Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept [J].

Shen, C ;

Assche, GV ;

Colpaert, S ;

Maerten, P ;

Geboes, K ;

Rutgeerts, P ;

Ceuppens, JL .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) :251-258

[10] The clinical spectrum of pulmonary aspergillosis [J].

Soubani, AO ;

Chandrasekar, PH .

CHEST, 2002, 121 (06) :1988-1999

← 1 2 →